ArticDX 002 a prospective study of MaculaRisk as a predictor of early progression of dry AMD to wet AMD (2010)

ArcticDx, Inc, a Toronto-based company, has developed a genetic test, Macula Risk®, to determine one’s inherited risk for age-related macular degeneration (AMD). AMD is the most common form of acquired blindness in the developed world, affecting over 10 percent of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.